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Risk of COVID-19-related death among patients with chronic 
obstructive pulmonary disease or asthma prescribed inhaled 
corticosteroids: an observational cohort study using the 
OpenSAFELY platform
Anna Schultze*, Alex J Walker*, Brian MacKenna*, Caroline E Morton*, Krishnan Bhaskaran, Jeremy P Brown, Christopher T Rentsch, 
Elizabeth Williamson, Henry Drysdale, Richard Croker, Seb Bacon, William Hulme, Chris Bates, Helen J Curtis, Amir Mehrkar, David Evans, 
Peter Inglesby, Jonathan Cockburn, Helen I McDonald, Laurie Tomlinson, Rohini Mathur, Kevin Wing, Angel Y S Wong, Harriet Forbes, John Parry, 
Frank Hester, Sam Harper, Stephen J W Evans, Jennifer Quint, Liam Smeeth, Ian J Douglas†, Ben Goldacre†, for the OpenSAFELY Collaborative
Summary
Background Early descriptions of patients admitted to hospital during the COVID-19 pandemic showed a lower 
prevalence of asthma and chronic obstructive pulmonary disease (COPD) than would be expected for an acute 
respiratory disease like COVID-19, leading to speculation that inhaled corticosteroids (ICSs) might protect against 
infection with severe acute respiratory syndrome coronavirus 2 or the development of serious sequelae. We assessed 
the association between ICS and COVID-19-related death among people with COPD or asthma using linked electronic 
health records (EHRs) in England, UK.
Methods In this observational study, we analysed patient-level data for people with COPD or asthma from primary 
care EHRs linked with death data from the Office of National Statistics using the OpenSAFELY platform. The index 
date (start of follow-up) for both cohorts was March 1, 2020; follow-up lasted until May 6, 2020. For the COPD cohort, 
individuals were eligible if they were aged 35 years or older, had COPD, were a current or former smoker, and were 
prescribed an ICS or long-acting β agonist plus long-acting muscarinic antagonist (LABA–LAMA) as combination 
therapy within the 4 months before the index date. For the asthma cohort, individuals were eligible if they were aged 
18 years or older, had been diagnosed with asthma within 3 years of the index date, and were prescribed an ICS or 
short-acting β agonist (SABA) only within the 4 months before the index date. We compared the outcome of COVID-
19-related death between people prescribed an ICS and those prescribed alternative respiratory medications: ICSs 
versus LABA–LAMA for the COPD cohort, and low-dose or medium-dose and high-dose ICSs versus SABAs only in 
the asthma cohort. We used Cox regression models to estimate hazard ratios (HRs) and 95% CIs for the association 
between exposure categories and the outcome in each population, adjusted for age, sex, and all other prespecified 
covariates. We calculated e-values to quantify the effect of unmeasured confounding on our results.
Findings We identified 148 557 people with COPD and 818 490 people with asthma who were given relevant respiratory 
medications in the 4 months before the index date. People with COPD who were prescribed ICSs were at increased 
risk of COVID-19-related death compared with those prescribed LABA–LAMA combinations (adjusted HR 1·39 
[95% CI 1·10–1·76]). Compared with those prescribed SABAs only, people with asthma who were prescribed high-
dose ICS were at an increased risk of death (1·55 [1·10–2·18]), whereas those given a low or medium dose were not 
(1·14 [0·85–1·54]). Sensitivity analyses showed that the apparent harmful association we observed could be explained 
by relatively small health differences between people prescribed ICS and those not prescribed ICS that were not 
recorded in the database (e value lower 95% CI 1·43).
Interpretation Our results do not support a major role for regular ICS use in protecting against COVID-19-related 
death among people with asthma or COPD. Observed increased risks of COVID-19-related death can be plausibly 
explained by unmeasured confounding due to disease severity.
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The ongoing pandemic due to severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) has affected over 
31 million people worldwide with at least 900 000 deaths 
due to COVID-19 as of Sept 23, 2020. People with more 
severe COVID-19 outcomes, including admission to 
hospital or death, are usually older and have pre-existing 
comorbidities.1–7 Severe outcomes are often a result of 
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lung complications, such as acute respiratory distress 
syndrome and respiratory failure. However, early reports 
of patients with COVID-19 described an unexpectedly low 
prevalence of chronic respiratory conditions among those 
who had been admitted to hospital.8 Although other 
studies suggest that chronic lung diseases, including 
chronic obstructive pulmonary disease (COPD), increase 
the risk of severe outcomes,5–7 reported effect sizes for 
asthma have been relatively small.5,6 These findings have 
led to speculation that treatments for respiratory disease, 
specifically inhaled corticosteroids (ICSs), might have a 
protective effect against SARS-CoV-2.8–11
ICSs are used to reduce airway inflammation, oedema, 
and mucus secretions.12 In-vitro evidence indicates that 
the ICS ciclesonide can suppress SARS-CoV-2 repli-
cation,13 and budesonide combined with glycopyrronium 
and formoterol has been shown to inhibit production of 
cytokines in cells exposed to human coronavirus 229E.14 
The orally or intravenously administered steroid dexam-
ethasone has been shown to reduce the risk of death in 
people with severe COVID-19.15 Conversely, although ICSs 
have low systemic absorption, in people with COPD they 
have been associated with an increased risk of developing 
pneumonia16–18 and other systemic steroid-related adverse 
effects.12 ICS use has also been shown to impair type 1 
interferon production, potentially increasing the risk of 
viral infections.19,20 A systematic review of the role of ICS 
use in SARS-CoV-2, severe acute respiratory syndrome 
coronavirus 1, and Middle East respiratory syndrome 
coronavirus identified no relevant articles addressing this 
question, and whether ICS use could influence either the 
risk of becoming infected with SARS-CoV-2 or the clinical 
prognosis of COVID-19 is unclear.9 Two ongoing 
randomised controlled trials are investigating whether the 
clinical course of COVID-19 is affected by ICS use 
(NCT04331054, NCT04330586); however, these trials will 
not address the role of regular ICS use on the risk of 
SARS-CoV-2 infection and outcomes among people who 
have an indication for ICS use, and, specifically, whether 
such use might have been responsible for the under-
representation of people with chronic respiratory disease 
in early epidemiological descriptions of COVID-19. To 
answer this question, we aimed to explore the association 
between current ICS use and COVID-19-related death 
among people with COPD and asthma using the 
OpenSAFELY platform, which runs across linked primary 
care electronic health record (EHR) data for approximately 
40% of the population in England, UK.
Methods
Study design, population, and data sources
In this observational study, we extracted data for two 
cohorts of patients, a cohort with COPD and a cohort 
with asthma, from primary care EHR data linked with 
death data from the Office for National Statistics. The 
index date (start of follow-up) for both cohorts was 
March 1, 2020; follow-up lasted until May 6, 2020.
Primary care records managed by the EHR vendor The 
Phoenix Partnership (TPP; Leeds, UK) were linked to 
death data from the UK Office for National Statistics 
Research in context 
Evidence before this study 
In March, 2020, at the start of the global COVID-19 pandemic, 
inhaled corticosteroids (ICSs) were hypothesised to offer some 
protection against either infection with severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) or against severe 
outcomes from COVID-19, such as acute respiratory distress 
syndrome and respiratory failure, despite these medications 
being known to increase the risk of pneumonia and other 
respiratory tract infections. The hypothesis was based at least in 
part on epidemiological data showing a low prevalence of 
chronic respiratory disease among Chinese patients with 
COVID-19, although some support of a potential protective 
effect also came from in-vitro studies. More recently, ICS 
exposure was found to correlate with a lower expression of ACE2 
and TMPRSS2, the entry receptors used by SARS-CoV-2, in 
sputum cells. A systematic review assessing whether ICSs were 
associated with clinical outcomes in COVID-19, severe acute 
respiratory syndrome, or Middle East respiratory syndrome 
identified no relevant studies. 
Added value of this study 
Our study was specifically designed to assess the role of 
routine ICS use in COVID-19-related mortality. We included 
two cohorts of participants: people with asthma, and people 
with chronic obstructive pulmonary disease (COPD), both of 
whom have a possible indication for ICS. Neither analysis was 
strongly suggestive that regular ICS therapy for asthma or 
COPD has a clinically important causal effect on COVID-19 
mortality in either direction. Our study includes data for 
almost 1 million patients, making it the largest contemporary 
study of ICS use in COVID-19 to date. We used active 
comparators and multiple sensitivity analyses to quantify the 
effect of possible unmeasured confounding. We used open 
methods throughout the study with code and codelists 
available for examination and reuse. 
Implications of all the available evidence
Evidence suggests there is neither a demonstrable benefit nor 
clear harm from ICS use against COVID-19-related mortality 
among people with COPD and asthma, and so no evidence 
supports that patients should alter their ICS therapies during 
the ongoing pandemic. Future observational research is likely 
to be subject to similar issues around unmeasured 
confounding, and evidence from ongoing randomised trials will 
provide answers regarding the role of ICS in the treatment of 
COVID-19 among people without asthma or COPD.
For the OpenSAFELY website 
see https://opensafely.org
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through OpenSAFELY, a data analytics platform created 
by our team on behalf of National Health Service 
(NHS) England21 to address urgent COVID-19 research 
questions.6 OpenSAFELY provides a secure software 
interface allowing the analysis of pseudonymised 
primary care patient records from England in near real-
time within the EHR vendor’s highly secure data centre, 
avoiding the need for large volumes of potentially 
disclosive pseudonymised patient data to be transferred 
offsite. This step, in addition to other technical and 
organisational controls, minimises any risk of re-
identification. Similarly pseudonymised datasets from 
other data providers are securely provided to the 
EHR vendor and linked using a salted hash (a securely 
pseudonomised identification key) generated from NHS 
numbers. Only records with matching NHS numbers 
are imported, and matching quality depends entirely on 
the accuracy of the NHS number. We are not able to 
determine the quality of the linkage because we do not 
have access to direct identifiers from external data 
sources. The dataset analysed within OpenSAFELY is 
based on 24 million people currently registered with 
primary care centres using TPP SystmOne software. The 
data managed by TPP includes pseudonymised data 
such as coded diagnoses, medications, and physiological 
parameters. No free-text data are included.
Individuals were eligible for the COPD cohort if they 
were aged 35 years and older, had COPD, and had 
current or former smoking recorded any time before 
the index date.22 For primary analyses, we also required 
individuals to be prescribed relevant respiratory 
medications, detailed in the Exposures section. We 
excluded indi viduals with a previous diagnosis of any 
other chronic respiratory conditions, if they had asthma 
in the 3 years before the index date,23 if they had received 
nebulised medications in the 12 months before the index 
date, or if they have received a leukotriene receptor 
antagonist (indicating potential asthma) in the 4 months 
before the index date. Nebulisers are a marker of severe 
respiratory disease or other underlying disability that 
prevents the use of an inhaler. Clinically, inclusion 
of such patients could further emphasise differences 
between groups and introduce additional confounding 
without contributing to the study question. However, few 
individuals were excluded due to this criterion (appendix 
pp 3–4).
Individuals were eligible for the asthma cohort if they 
were aged 18 years or older with asthma recorded within 
3 years before the index date. We excluded those with 
COPD or other chronic respiratory conditions before the 
index date, and those who were receiving a long-acting 
muscarinic antagonist (LAMA) without an ICS because 
this is an indication of possible COPD.24  For primary 
analyses, we also required individuals to be prescribed 
relevant respiratory medications, detailed in the Exposures 
section. As in the COPD cohort, those receiving nebulised 
medications in the 12 months before the index date were 
excluded. For both cohorts, people with missing data for 
sex or index of multiple deprivation, or with less than 1 year 
of primary care records were excluded (appendix p 2).
This study was approved by the Health Research 
Authority (Research Ethics Committee reference 
20/LO/0651) and by the London School of Hygiene & 
Tropical Medicine ethics board (reference number 21863). 
No further ethical or research governance approval was 
required by the University of Oxford (Oxford, UK) but 
copies of the approval documents were reviewed and held 
on record. Participant consent was not required because 
of regulation 3(4) of the Health Service (Control of Patient 
Information) Regulations 2002; the legal gateways 
involved for General Data Protection Regulations did not 
require consent. All iterations of the prespecified study 
protocol are archived with version control and available 
online. Patients were not formally involved in developing 
the study design, which was developed rapidly in the 
context of a global health emergency; however, the first 
draft of the manuscript was sent to the Asthma UK and 
British Lung Foundation Partnership who provided 
review, comment, and suggestions from an expert patient 
perspective. We have also developed the OpenSAFELY 
website through which we invite any patient or member 
of the public to contact us regarding this study or the 
broader OpenSAFELY project.
Exposures
In the COPD population, people issued at least one ICS 
prescription within 4 months before the index date either 
in combination with long-acting β agonist (LABA) or 
LABA–LAMA, or as single therapy (provided they also 
had at least one prescription record of a LABA in the past 
4 months), were compared with those with a prescription 
for a LABA–LAMA (combined or as separate single 
therapy prescriptions) only.24 We did not include patients 
who had been given LAMA monotherapy in our primary 
analyses because we were expecting improved clinical 
comparability between the LABA–LAMA and ICS-based 
therapy groups, following existing National Institute for 
Health and Care Excellence guidance.24–27 The inclusion of 
patients on LAMA mono therapy was assessed in a 
sensitivity analysis.
In the asthma population, people prescribed high-
dose ICS and low-dose or medium-dose ICS during the 
4 months before the index date were compared with 
those prescribed short-acting β agonists (SABAs) only. 
Exposure for people prescribed both high-dose and low-
dose or medium-dose ICS was assigned according to 
their most recent prescription. Prescriptions for 
inhalers were assigned to low or medium dose or high 
dose using the OpenPrescribing prescribing explorer 
based on British Thoracic Society and Scottish 
Intercollegiate Guidelines Network guidance.28 Studies 
have found that a substantial proportion of people with 
asthma receiving SABAs only are eligible for ICS 
treatment,29 suggesting some similarity in terms of 
See Online for appendix
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disease severity with those prescribed ICSs, and 
therefore we hypothesised that they could represent a 
reasonable active comparator group. The characteristics 
of all other individuals are described in the appendix 
(pp 5–12); however, they are excluded from regression 
models to avoid comparisons to individuals not 
prescribed drugs of interest.30
Outcomes
The outcome of interest was COVID-19-related death as 
registered in data from the Office for National Statistics 
using International Classification of Diseases 10th edition 
(ICD-10) codes U07.1 (“COVID-19, virus identified”) and 
U07.2 (“COVID-19, virus not identified”) listed either as 
the underlying or any contributing cause of death. The 
U07.2 ICD-10 code is used when laboratory testing is 
inconclusive or unavailable but a clinical diagnosis 
indicates COVID-19.31
Covariates
Potential determinants of exposures and outcomes were 
identified by reviewing the literature and through 
discussions with practising clinicians. Because this is a 
study of current users of prespecified treatments, 
determinants of exposures include both factors that 
might affect the initial choice of treatment and those that 
affect whether a patient remains on a specific treatment. 
The final list of potential confounders is in the panel. 
Our methods for creating codelists have been 
previously described;6 these methods included clinical 
and epidemiological review and sign-off by at least two 
authors. Detailed information on every codelist is 
available online.
Statistical methods
All eligible individuals were included; we did not do 
sample size calculations because the sample size was 
fixed by the size of the database.
We summarised individuals’ characteristics using 
descriptive statistics, stratified by exposure status. We 
used Kaplan-Meier plots to show time to the primary 
outcome, with time in study as the timescale. We 
dealt with the competing risk of death from non-COVID-
19-realated causes by analysing the cause-specific 
hazard, with people dying from other causes censored at 
their date of death.36 We used Cox regression 
models to estimate hazard ratios (HRs) and 95% CIs for 
the association between exposure categories and the 
outcome in each population. We fitted univariable 
models, models adjusted for age (using restricted cubic 
splines) and sex, and fully adjusted models including all 
covariates (panel). We included the Sustainability and 
Transformation Partnership (an NHS admini s-
trative region) of the patient’s primary care clinic as a 
stratification variable in fully adjusted models. We assessed 
a prespecified interaction between ICS exposure and age 
to see if we could distinguish a differential effect in groups 
known to be at increased risk of COVID-19-related death. 
We also did post-hoc analyses adjusting for each one of the 
prespecified comorbidities at a time (panel).
We assessed the proportional hazards assumption by 
testing for a zero slope in the scaled Schoenfeld residuals 
Panel: Prespecified hypothetical confounders
All covariates were defined using primary care data only, using 
either information recorded in the electronic health record or 
diagnostic codes, or both. The analytical programs titled 
“study_definition”, available on our Github repository, provide 
the complete details of variable definitions. We used the same 
definitions irrespective of the exposure category an individual 
belonged to: 
• Age (in years) as of the index date, derived from patient’s 
date of birth 
• Sex (male, female)
• BMI most recent measurement in the past decade32
• Indices of multiple deprivation: quintiles from index of 
multiple deprivation 201933 
• Diagnosed hypertension
• Heart disease: categorised as heart failure and other heart 
disease
• Diabetes: categorised as controlled (HbA1c <7·5% 
[<58 mmol/mol]), uncontrolled (HbA1c ≥7·5% [≥58 mmol/mol]), 
or HbA1c not measured within 12 months of index date
• Cancer
• Immunosuppressive conditions: organ transplant, sickle cell 
anaemia, and splenectomy
• Chronic kidney disease: based on creatinine measurements 
within 12 months of the index date or ever having a read 
code for renal dialysis
• Influenza vaccination status: recorded within 6 months of 
the index date
• Pneumococcal vaccination status: recorded in the 5 years 
before the index date
• Statin use: recorded within 4 months before the index date
• Exacerbation history: different methods used for asthma34 
and COPD population;35 briefly, asthma exacerbations were 
defined using prescriptions of oral steroids without a 
concurrent diagnosis indicating these were prescribed for a 
different indication; and COPD exacerbations were defined 
using an approach proposed in a previous validation study,35 
defined as a diagnostic code for a lower respiratory tract 
infection or COPD exacerbation, excluding those occurring 
on the same date as an annual review or use of a prescription
• COPD models were additionally adjusted for a history of 
asthma
BMI=body-mass index. COPD=chronic obstructive pulmonary disease. HbA1c=glycated 
haemoglobin.
For a full list of codelists see 
https://codelists.opensafely.org
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and through graphical inspection of plots of the 
Schoenfeld residuals against time.
To derive marginal effect estimates, we generated 
cumulative mortality curves standardised to adjust for 
differences in the covariate distributions between 
people exposed and not exposed to ICS. First, we fitted 
a flexible parametric Royston-Parmar model with the 
same covariates as the main Cox regression, with the 
baseline hazard modelled using a three (COPD) or two 
(asthma) degrees-of-freedom spline. We predicted the 
survival function from this model for every individual 
with the exposure set to each of the exposure levels in 
the COPD and asthma population in turn; we then 
averaged the predictions to produce population-level 
curves. We also used these models to estimate an 
adjusted absolute survival difference at the end of 
follow-up.
We did several sensitivity analyses. First, we split the 
exposure categories in the COPD population to examine 
the effect of ICS with LABA–LAMA (triple combination) 
and ICS with LABA (dual combination) separately, 
anticipating increased underlying disease severity in 
people prescribed triple therapy. Second, we restricted 
analyses to the largest ethnic group (ie, white) to exclude 
any substantial confounding by ethnicity. We did not 
adjust for ethnicity in the main models because we did 
not anticipate this variable to be a strong confounder and 
due to a sizable proportion of individuals with missing 
ethnicity (23–24% across treatment categories). In the 
asthma population, we varied the sample definition to 
include people with asthma diagnosed at any time, and a 
prescription for any asthma medication within 4 months 
of the index date. In the COPD population, we included 
people who were prescribed LAMA monotherapy in the 
comparator group to investigate the effect of the choice to 
exclude this patient group in the main analyses. We also 
investigated additional adjustment for oral steroid use in 
the COPD population, for whom this variable did not 
form part of the exacerbation definition. Finally, post hoc, 
we re-ran the analyses using inverse probability of 
treatment-weighted Cox regressions, weighted using 
propensity scores derived from logistic (COPD) and 
multinomial logistic (asthma) models. Further details of 
these methods are in the appendix (p 30).
We hypothesised that respiratory disease severity, but 
not ICS use, might influence the risk of non-COVID-19-
related death. Therefore, we did prespecified exploratory 
analyses using non-COVID-19-related death as a negative 
control outcome, censoring people at time of COVID-19-
related death. If any potentially harmful association 
observed in primary analyses was due to confounding (ie, 
people prescribed ICS had more severe underlying 
respiratory disease than those who did not) we expected 
to observe a similar association with non-COVID-19-
related death in people prescribed ICS.
Quantitative bias analysis is a type of sensitivity analysis 
that can be used to assess the role that unmeasured 
confounders might have in observational analyses. We 
used one form of quantitative bias analysis here 
specifically, we calculated an e value, which quantifies 
the strength of association between an unmeasured 
confounder and exposure or outcome, conditional on 
measured covariates, that would be necessary to fully 
explain observed associations.37
We managed the data using Python (version 3.8) and 
SQL, with analysis carried out using Stata (version 16.1). 
All code we used for data management and analyses is 
openly shared online on our GitHub page. All raw model 
outputs can be viewed online in the accompanying 
released output and log files that have had small 
numbers redacted. We followed both Strengthening the 
Reporting of Observational Studies in Epidemiology and 
Reporting of studies Conducted using Observational 
Routinely Collected Health Data Statement for Pharmaco-
epidemiology guidelines (appendix pp 40–43).
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. AS, AJW, CEM, SB, WH, CB, JC, 
LS, and BG had access to the raw data. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Of 33 356 521 individuals in our linked database, 
148 557 people with COPD and 818 490 people with 
asthma and a relevant prescription within the 4 months 
before the index date were eligible for inclusion in our 
two cohorts (appendix pp 3–4).
Demographic and clinical characteristics of the COPD 
population are shown in table 1. 43 308 (29·2%) of 
148 557 individuals in this population had been given a 
LABA–LAMA prescription in the 4 months before the 
index date, and 105 249 (70·8%) had been given prescrip-
tions for ICS–LABA or ICS–LABA–LAMA (ie, ICS 
combination). Demographic characteristics of treatment 
groups were similar. The median follow-up time was 
66 days (IQR 66–66) in both groups (appendix p 39). The 
presence of comorbidities was similar between the two 
treatment groups, except asthma diagnosis in the 3 years 
before the index date, which was more common among 
people prescribed an ICS. The proportion of people with 
an exacerbation in the past year was lower among people 
prescribed a LABA–LAMA combination than those 
prescribed an ICS combination.
Demographic and clinical characteristics of the asthma 
population are shown in table 2. 608 972 (74·4%) of 
818 490 individuals had a prescription for low-dose or 
medium-dose ICS in the 4 months before the index date, 
101 077 (12·3%) had a prescription for a high-dose ICS, and 
108 441 (13·2%) had a prescription for a SABA only. The 
asthma treatment groups differed in terms of demographic 
For our GitHub page see 
https://github.com/opensafely/
ics-research
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and clinical characteristics. The median age was 48 years 
(IQR 35–60) in the SABA only group, 53 years (40–66) in 
the low-dose or medium-dose ICS group, and 55 years 
(44–67) in the high-dose ICS group. The proportion of men 
was slightly higher among people prescribed SABA only 
(46 614 [43·0%]) than in the low-dose or medium-dose ICS 
group (245 446 [40·3%]) and high-dose ICS group 
(38 590 [38·2%]). The median follow-up time was 66 days 
(IQR 66–66) in all groups. The prevalence of most 
comorbidities was lowest among people prescribed SABA 
only and highest among those prescribed high-dose ICS. 
The SABA only group had the lowest proportion of 
individuals with an asthma exacerbation in the past year 
(15 210 [14·0%]), and the high-dose ICS group had the 
highest proportion (36 726 [36·3%]).
429 COVID-19-related deaths occurred in the 
COPD population. Time to COVID-19-related death by 
treatment group is shown in figure 1A. In univariable 
models, compared with people prescribed LABA–LAMA 








18–<40 85 (0·2%) 184 (0·2%)
40–<50 1060 (2·5%) 2291 (2·2%)
50–<60 5749 (13·3%) 12 245 (11·6%)
60–<70 12 607 (29·1%) 29 530 (28·1%)
70–<80 16 106 (37·2%) 40 380 (38·4%)
≥80 7701 (17·8%) 20 619 (19·6%)
Median 71 (63–77) 72 (64–78)
Mean 70·0 (10·1) 70·8 (10·1)
Range 35–100 35–102
Sex
Female 19 717 (45·5%) 48 731 (46·3%)
Male 23 591 (54·5%) 56 518 (53·7%)
BMI grouping 
Underweight (<18·5 kg/m²) 1683 (3·9%) 4740 (4·5%)
Normal (18·5 to <25 kg/m²) 12 949 (29·9%) 31 865 (30·3%)
Overweight (25 to <30 kg/m²) 14 019 (32·4%) 33 514 (31·8%)
Obese I (30 to <35 kg/m²) 8593 (19·8%) 20 281 (19·3%)
Obese II (35 to <40 kg/m²) 3572 (8·3%) 8386 (8·0%)
Obese III (≥40 kg/m²) 1581 (3·7%) 3948 (3·8%)
Missing 911 (2·1%) 2515 (2·4%)
Smoking status
Never 0 0
Former 26 040 (60·1%) 69 740 (66·3%)
Current 17 268 (39·9%) 35 509 (33·7%)
Missing 0 0
Ethnicity
White 32 498 (75·0%) 79 735 (75·8%)
Mixed 92 (0·2%) 182 (0·2%)
Asian or Asian British 260 (0·6%) 836 (0·8%)
Black 103 (0·2%) 301 (0·3%)
Other 112 (0·3%) 289 (0·3%)
Unknown 10 243 (23·7%) 23 906 (22·7%)
Index of Multiple Deprivation
1 (least deprived) 8066 (18·6%) 19 896 (18·9%)
2 8426 (19·5%) 20 629 (19·6%)
3 8757 (20·2%) 21 244 (20·2%)
4 8425 (19·5%) 21 641 (20·6%)
5 (most deprived) 9634 (22·3%) 21 839 (20·%)
Missing 0 0






(Continued from previous column)
Treatments
Single SABA 30 945 (71·5%) 83 683 (79·5%)
High-dose ICS 0 25 467 (24·2%)
Low-dose or medium-dose ICS 0 82 506 (78·4%)
Single ICS 0 2325 (2·2%)
Single SAMA 157 (0·4%) 1488 (1·4%)
Single LABA 2433 (5·6%) 855 (0·8%)
Single LAMA 4590 (10·6%) 45 483 (43·2%)
LABA–ICS 0 75 552 (71·8%)
LABA–LAMA 41 377 (95·5%) 4807 (4·6%)
LABA–LAMA–ICS 0 33 040 (31·4%)
Single LTRA 0 0
Clinical conditions
Chronic kidney disease
No 35 570 (82·1%) 86 886 (82·6%)
Yes 7738 (17·9%) 18 363 (17·4%)
Hypertension
No 21 607 (49·9%) 50 954 (48·4%)
Yes 21 701 (50·1%) 54 295 (51·6%)
Heart failure
No 39 445 (91·1%) 95 283 (90·5%)
Yes 3863 (8·9%) 9966 (9·5%)
Other heart diseases
No 33 253 (76·8%) 81 128 (77·1%)
Yes 10 055 (23·2%) 24 121 (22·9%)
Cancer
No 37 073 (85·6%) 90 171 (85·7%)
Yes 6235 (14·4%) 15 078 (14·3%)
Diabetes
No diabetes 32 913 (76·0%) 79 549 (75·6%)
Diabetes, not severe 7586 (17·5%) 19 030 (18·1%)
Diabetes, severe 2712 (6·3%) 6 366 (6·0%)
Diabetes, no HbA1C 
measurement
97 (0·2%) 304 (0·3%)
Recent statin use 
No 20 531 (47·4%) 50 912 (48·4%)
Yes 22 777 (52·6%) 54 337 (51·6%)
Influenza vaccine status
(Table 1 continues in next column)
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an increased risk of COVID-19-related death (HR 1·53 
[95% CI 1·22–1·93]; figure 2). This association decreased 
after adjustment for age and sex (1·43 [1·13–1·80]), and 
in the fully adjusted model (1·39 [1·10–1·76]; figure 2). 
Post-hoc analyses showed that adjustment for previous 
exacer bations as a binary variable, smoking status, and 
index of multiple deprivation had the largest effect on 
reducing the association; adjustment for other individual 
potential confounders had a negligible effect on the 
effect estimate (appendix pp 17–18). We found no 
evidence of a (prespecified) interaction with age 
(appendix p 14). We detected some evidence of deviations 
from the proportional hazards assumptions (appendix 
pp 15–16). The Kaplan-Meier curve indicated that the 
HR was probably above 1 throughout the follow-up 
period, with the effect size growing slightly over time 
(figure 1A).
We generated standardised survival curves for the COPD 
population (figure 1C). At the end of follow-up, estimated 
cumulative mortality was 0·31% (95% CI 0·28–0·35) in 
the ICS combination group and 0·22% (0·17–0·27) in the 
LABA–LAMA combination group. The adjusted absolute 
cumulative risk difference between the two treatment 
groups at the end of follow-up was 0·09% (0·03–0·15).
529 COVID-19-related deaths occurred in the asthma 
population. Time to COVID-19-related death by treatment 
group is shown in figure 1B. In univariable models, 
people prescribed both low-dose or medium-dose ICS 
and high-dose ICS were at an increased risk of COVID-
19-related death compared with those prescribed SABA 
only (HR 1·36 [95% CI 1·01–1·84] for low or medium 
dose; 2·30 [1·64–3·23] for high dose; figure 3). These 
associations reduced substantially after adjustment for 
age and sex (1·02 [0·76–1·37] for low or medium dose; 
1·61 [1·15–2·27] for high dose), and in fully adjusted 
models (1·14 [0·85–1·54] for low or medium dose; 
1·55 [1·10–2·18] for high dose; figure 3). Post-hoc 
analyses revealed that the greatest reduction in the 
strength of the association between high-dose ICS and 
COVID-19-related mortality, after adjustment for age and 
sex, was adjustment for previous exacerbations; 
adjustment for other individual potential con founders 
had a negligible effect on the effect estimate 
(appendix pp25–26). We found no evidence for a 
(prespecified) interaction with age, and no deviations 
from the proportional hazards assumption (appendix 
pp 20–24).
We generated standardised survival curves for the 
asthma population (figure 1D). At the end of 
follow-up, the estimated cumulative mortality was 0·07% 
(95% CI 0·06 to 0·09) in the high-dose ICS group, 
0·05% (0·05 to 0·06) in the low-dose ICS group, 
and 0·05% (0·03 to 0·07) in the SABA only group. The 
adjusted absolute cumulative risk difference was 0·005% 
(–0·0012 to 0·002) comparing the low-dose or medium-
dose ICS group with the SABA only group and 0·03% 
(0·003 to 0·05) comparing the high-dose ICS group to 
the SABA only group.
In our sensitivity analyses, when considering the dual 
combination of ICS–LABA and the triple combination of 
ICS–LABA–LAMA separately in the COPD population 
compared with the main analysis, the risk of death was 
increased among those prescribed triple combination 
therapy (fully adjusted HR 1·43 [95% CI 1·12–1·83]) but 
this increase was less substantial among those 
prescribed dual combination therapy (1·29 [0·96–1·74]; 
figure 2). Restricting analyses to people of white ethnicity 
led to a reduction in the HRs in the COPD population 
(figure 2), but not in the asthma population (figure 3). 
Changing the population definition for the asthma 
population had a negligible effect on the results 
(figure 3). Including people receiving LAMA mono-
therapy in the COPD comparator group also did not 
substantially affect the main effect estimates (figure 2), 
and additional adjustment for oral steroid use in the 
COPD population when this did not form part of the 






(Continued from previous column)
No 8689 (20·1%) 19 917 (18·9%)
Yes 34 619 (79·9%) 85 332 (81·1%)
Pneumococcal vaccine status
No 32 285 (74·5%) 83 943 (79·8%)
Yes 11 023 (25·5%) 21 306 (20·2%)
Exacerbation in past year
No 34 774 (80·3%) 77 897 (74·0%)
Yes 8534 (19·7%) 27 352 (26·0%)
Asthma ever*
No 37 731 (87·1%) 76 063 (72·3%)
Yes 5577 (12·9%) 29 186 (27·7%)
Immunosuppressed (combination algorithm)
No 43 211 (99·8%) 105 013 (99·8%)
Yes 97 (0·2%) 236 (0·2%)
Primary care physician consultation count
Median 10 (6–16) 10 (6–17)
Mean 12·7 (11·4) 13·5 (12·3)
Range 0–276 0–306
Exacerbation count in the past year
Median 0 (0–0) 0 (0–1)
Mean 0·26 (0·60) 0·38 (0·77)
Range 0–9 0–12
Data are n (%), median (IQR), mean (SD), or range. Some proportions might not 
add up to 100% due to rounding. BMI=body-mass index. COPD=chronic 
obstructive pulmonary disease. HbA1c=glycated haemoglobin. ICS=inhaled 
corticosteroid. LABA=long-acting β agonist. LAMA=long-acting muscarinic 
antagonist. LTRA=leukotriene receptor antagonist. SABA=short-acting β agonist. 
SAMA=short-acting muscarinic antagonist. *Asthma diagnosed >3 years before 
index date.
Table 1: Demographic and clinical characteristics of patients in the COPD 
cohort
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effect estimate (appendix pp 18). Finally, re-running 
the analyses using propensity scores incorporated 
through inverse probability of treatment-weighted Cox 
regressions did not change the effect estimates 
(figures 2, 3; appendix p 38).
In the COPD population, the risk of non-COVID-19-
related death was higher among individuals prescribed 
ICS than in those prescribed LABA–LAMA with an 
adjusted HR of 1·23 (95% CI 1·08–1·40; figure 2). In the 
asthma population, we found no evidence of an increased 
risk of non-COVID-19-related death among individuals 
prescribed high-dose or low-dose or medium-dose ICS 
compared with those prescribed SABA only (figure 3).
Given that we observed a harmful association between 
ICS and COVID-19 death, we used quantitative bias 
analysis to see how much unadjusted confounding 
SABA only (n=108 411) ICS
Low or medium dose (n=608 972) High dose (n=101 077)
Demographics
Age
18–<40 36 264 (33·4%) 144 955 (23·8%) 18 836 (18·6%)
40–<50 22 067 (20·4%) 107 835 (17·7%) 18 459 (18·3%)
50–< 60 21 852 (20·2%) 130 434 (21·4%) 23 752 (23·5%)
60–<70 13 974 (12·9%) 105 897 (17·4%) 18 970 (18·8%)
70–<80 9209 (8·5%) 79 810 (13·1%) 13 904 (13·8%)
≥80 5075 (4·7%) 40 041 (6·6%) 7156 (7·1%)
Median 48 (35–60) 53 (40–66) 55 (44–67)
Mean 48·3 (17·4) 53·1 (17·4) 55·0 (16·4)
Range 18–106 18–106 18–106
Sex
Female 61 827 (57·0%) 363 526 (59·7%) 62 487 (61·8%)
Male 46 614 (43·0%) 245 446 (40·3%) 38 590 (38·2%)
BMI grouping
Underweight (<18·5 kg/m²) 1637 (1·5%) 7623 (1·3%) 1147 (1·1%)
Normal (18·5 to <25 kg/m²) 28 141 (26·0%) 153 022 (25·1%) 20 955 (20·7%)
Overweight (25 to <30 kg/m²) 32 874 (30·3%) 196 599 (32·3%) 30 763 (30·4%)
Obese I (30 to <35 kg/m²) 20 069 (18·5%) 122 212 (20·1%) 22 297 (22·1%)
Obese II (35 to <40 kg/m²) 9497 (8·8%) 56 837 (9·3%) 11 891 (11·8%)
Obese III (≥40 kg/m²) 5937 (5·5%) 34 102 (5·6%) 8248 (8·2%)
Missing 10 286 (9·5%) 38 577 (6·3%) 5776 (5·7%)
Smoking status
Never 45 384 (41·9%) 268 922 (44·2%) 41 231 (40·8%)
Former 42 272 (39·0%) 254 334 (41·8%) 44 137 (43·7%)
Current 20 625 (19·0%) 85 414 (14·0%) 15 665 (15·5%)
Missing 160 (0·2%) 302 (0·1%) 44 (<0·1%)
Ethnicity
White 74 402 (68·6%) 428 142 (70·3%) 71 303 (70·5%)
Mixed 978 (0·9%) 5028 (0·8%) 838 (0·8%)
Asian or Asian British 5698 (5·3%) 32 357 (5·3%) 5866 (5·8%)
Black 1546 (1·4%) 8139 (1·3%) 1455 (1·4%)
Other 892 (0·8%) 4863 (0·8%) 881 (0·9%)
Unknown 24 925 (23·0%) 130 443 (21·4%) 20 734 (20·5%)
Index of Multiple Deprivation 
1 (least deprived) 21 087 (19·5%) 124 406 (20·4%) 17 776 (17·6%)
2 21 705 (20·0%) 124 312 (20·4%) 18 956 (18·8%)
3 22 016 (20·3%) 121 926 (20·0%) 20 217 (20·0%)
4 22 392 (20·7%) 121 117 (19·9%) 21 478 (21·2%)
5 (most deprived) 21 241 (19·6%) 117 211 (19·3%) 22 650 (22·4%)
Missing 0 0 0
(Table 2 continues on next page)
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SABA only (n=108 411) ICS
Low or medium dose (n=608 972) High dose (n=101 077)
(Continued from previous page)
Treatments
Single SABA 108 441 (100%) 417 008 (68·5%) 78 222 (77·4%)
High-dose ICS 0 2914 (0·5%) 101 077 (100%)
Low-dose or medium-dose ICS 0 608 972 (100%) 7547 (7·5%)
Single ICS 0 280 880 (46·1%) 10 088 (10·0%)
Single SAMA 116 (0·1%) 1630 (0·3%) 896 (0·9%)
Single LABA 543 (0·5%) 5960 (1·0%) 1503 (1·5%)
Single LAMA 0 8037 (1·3%) 8335 (8·3%)
LABA–ICS 0 338 182 (55·5%) 93 459 (92·5%)
LABA–LAMA 0 236 (<0·1%) 121 (0·1%)
LABA–LAMA–ICS 0 1177 (0·2%) 86 (0·1%)
Single LTRA 0 40 468 (6·7%) 23 054 (22·8%)
Clinical conditions
Chronic kidney disease
No 103 341 (95·3%) 573 525 (94·2%) 94 026 (93·0%)
Yes 5100 (4·7%) 35 447 (5·8%) 7051 (7·0%)
Hypertension
No 82 598 (76·2%) 432 452 (71·0%) 67 206 (66·5%)
Yes 25 843 (23·8%) 176 520 (29·0%) 33 871 (33·5%)
Heart failure
No 106 459 (98·2%) 596 359 (97·9%) 98 081 (97·0%)
Yes 1982 (1·8%) 12 613 (2·1%) 2996 (3·0%)
Other heart diseases
No 101 549 (93·7%) 565 066 (92·8%) 91 929 (90·9%)
Yes 6892 (6·4%) 43 906 (7·2%) 9148 (9·1%)
Cancer
No 102 740 (94·7%) 571 390 (93·8%) 94 325 (93·3%)
Yes 5701 (5·3%) 37 582 (6·2%) 6752 (6·7%)
Diabetes
No diabetes 93 589 (86·3%) 523 874 (86·0%) 83 064 (82·2%)
Diabetes, not severe 8946 (8·3%) 57 866 (9·5%) 12 254 (12·1%)
Diabetes, severe 5 551 (5·1%) 25 283 (4·2%) 5436 (5·4%)
Diabetes, no HbA1c 355 (0·3%) 1949 (0·3%) 323 (0·3%)
Recent statin use
No 90 340 (83·3%) 475 969 (78·2%) 74 854 (74·1%)
Yes 18 101 (16·7%) 133 003 (21·8%) 26 223 (25·9%)
Influenza vaccine status
No 65 191 (60·1%) 240 861 (39·6%) 36 016 (35·6%)
Yes 43 250 (39·9%) 368 111 (60·5%) 65 061 (64·4%)
Pneumococcal vaccine status
No 101 846 (93·9%) 557 804 (91·6%) 91 105 (90·1%)
Yes 6595 (6·1%) 51 168 (8·4%) 9972 (9·9%)
Exacerbation in past year
No 93 231 (86·0%) 487 282 (80·0%) 64 351 (63·7%)
Yes 15 210 (14·0%) 121 690 (20·0%) 36 726 (36·3%)
Immunosuppressed (combination algorithm)
No 108 056 (99·6%) 607 221 (99·7%) 100 762 (99·7%)
Yes 385 (0·4%) 1751 (0·3%) 315 (0·3%)
(Table 2 continues on next page)
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would need to be present in our data to account for this 
result, if in reality, the risk of COVID-19-related death is 
not affected by ICS use. To make our results consistent 
with a null effect—ie, to fully explain the lower bound of 
the fully adjusted 95% CI in the COPD cohort (1·10), or 
for the high-dose ICS association in the asthma 
cohort (1·10)—an unmeasured confounder would need 
to be associated (conditional on measured covariates) 
with either exposure or outcome by a risk ratio of at 
least 1·43 (e value; appendix p 28). An unmeasured 
confounder would need to have a stronger association 
with either exposure or outcome to move the observed 
HRs to a protective effect of 0·8 (e value COPD: 2·87, 
asthma: 3·29, appendix p 29).
Discussion
We have investigated the association between regular ICS 
use and COVID-19-related death among people with 
chronic respiratory disease in England. In a cohort of 
people with COPD, the HR for COVID-19-related death 
among those prescribed ICS combinations compared 
with people prescribed LABA–LAMA combinations was 
1·39 (95% CI 1·10–1·76) in the fully adjusted model, 
although this statistic does not mean the difference was 
caused by their ICS prescription. In the asthma cohort, 
those prescribed high-dose ICS had an HR for COVID-
19-related death of 1·55 (95% CI 1·10–2·18) compared 
with those prescribed SABA only in the fully adjusted 
model, with little evidence of any increased relative risk of 
death among those prescribed low-dose or medium-dose 
ICS (1·14 [0·85–1·54]). Notably, absolute risks of death 
were very low, with the estimated cumulative COVID-19-
related mortality only 0·09% higher in the ICS group 
than in the LABA–LAMA group in the COPD population, 
and 0·03% higher in the high-dose ICS group than in 
the SABA only group in the asthma population. Taken 
together, our findings do not provide any strong support 
for a protective effect from ICS use in these populations, 
as has been previously hypothesised might exist.
The observed harmful associations between ICS 
prescription and COVID-19-related death could be readily 
explained by confounding due to underlying health 
differences between people prescribed ICS and those 
using other medications for asthma and COPD, 
differences that cannot be measured using EHR data, 
rather than representing a causally harmful effect of ICS. 
In support of this interpretation, we observed a higher 
risk of COVID-19-related death among people prescribed 
ICS triple therapy than in those prescribed dual therapy in 
the COPD cohort. The ICS content of these two regimens 
is similar, and any putative causal effect of ICS would be 
expected to be similar in these two groups. If it had been 
possible to successfully control for differences in disease 
severity between treatment groups, we would also expect 
to see no increased risk of death in the ICS groups for the 
negative control outcome of non-COVID-19-related death. 
The harmful association between ICS use and non-
COVID-19-related death we observed suggests we were 
not able to capture all markers of disease severity using 
patients’ EHR data, resulting in an observed association 
that is unlikely to be causal. The absence of an increased 
risk of non-COVID-19-related death among people 
prescribed ICS combinations in the asthma cohort is 
perhaps not surprising because the association between 
asthma and overall mortality is much smaller than that for 
COPD.38 Finally, quantitative bias analysis confirmed that 
a hypothetical unmeasured confounder of moderate 
strength could fully explain the observed results.
Notably, had ICS been responsible for the protective 
effect alluded to in previous descriptive studies,8,10,11 we 
would expect to detect such an association in our study 
irrespective of unmeasured confounding by indication. 
We would expect to see this association because these 
descriptive studies have compared the risk of severe 
COVID-19 outcomes among patients with respiratory 
disease, only some of whom use ICSs, to those without 
any respiratory disease at all8 or those with only mild 
disease.11 To explain any reduced risk in these studies, the 
SABA only (n=108 411) ICS
Low or medium dose (n=608 972) High dose (n=101 077)
(Continued from previous page)
Primary care physician consultation count
Median 6 (3–12) 7 (4–13) 9 (5–16)
Mean 9·3 (10·7) 10·3 (11·2) 12·8 (13·5)
Range 0–296 0–548 0–604
Exacerbation count in the past year
Median 0 (0–0) 0 (0–0) 0 (0–1)
Mean 0·24 (0·95) 0·35 (1·09) 0·81 (1·71)
Range 0–16 0–17 0–17
Data are n (%), median (IQR), mean (SD), or range. Some proportions might not add up to 100% due to rounding. BMI=body-mass index. HbA1c=glycated haemoglobin. 
ICS=inhaled corticosteroid. LABA=long-acting β-agonist. LAMA=long-acting muscarinic antagonist. LTRA=leukotriene receptor antagonist. SABA=short-acting β agonist. 
SAMA=short-acting muscarinic antagonist. 
Table 2: Demographic and clinical characteristics for patients in asthma cohort
Articles
1116 www.thelancet.com/respiratory   Vol 8   November 2020
effect of ICS use would have to be strong enough to 
overcome both unmeasured confounding due to 
differences in respiratory disease severity and a dilution 
of effect because not all patients will have been prescribed 
ICSs. Therefore, although unmeasured confounding is a 
plausible explanation for the harmful effect we observed, 
it cannot fully explain the absence of a protective effect of 
the size that would have to exist according to the original 
hypothesis.
To our knowledge, no other epidemiological studies or 
randomised controlled trials assessing the role of regular 
ICS use in COVID-19 among people with an indication have 
been done to date. Two randomised trials investigating the 
role of ICS use in people who have been admitted to 
hospital with laboratory-confirmed SARS-CoV-2 infection 
(NCT04331054) and mild COVID-19 (NCT04330586) are 
ongoing. The hypothesis of a protective effect of ICS in 
COVID-19 was partly based on the low prevalence of chronic 
lung disease among outpatient and inpatient COVID-19 
cases in China.8 However, subsequent studies do not support 
initial assertions that people with chronic lung diseases 
(including COPD) are substantially under-represented 
among patients with COVID-19.5,6,39 Additionally, a few 
studies have found that people with COPD are at increased 
risk of severe COVID-19 and death from COVID-19.5,6 The 
evidence for an association between asthma and COVID-19 
severity is more varied, with studies reporting both null and 
moderately harmful associations.5,6 Among people with 
asthma, features other than ICS use (eg, shielding) might 
affect the risk of acquiring SARS-CoV-2. Studies investigating 
the causal effect of chronic respiratory disease, including 
COPD and asthma, on the risk of SARS-CoV-2 infection and 
COVID-19 severity, ideally taking into account the relatively 
large degree of heterogeneity that exists in each of these 
diagnostic categories, are urgently needed to help inform 
decisions around levels of risk for these individuals.
The greatest strength of this study was our ability to 
look at multiple drug treatments because our dataset 
included medical records from more than 30 million 
individuals. Our study is further strengthened by our use 
of two different study populations and active comparators, 
and sensitivity analyses to quantify the potential effect of 
unmeasured confounding on results. Finally, we used 
open methods: we prespecified our analysis plan and 
have shared all analytical code.
Our study has several limitations. The primary limit-
ation is the risk of confounding by indication due to 
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Unadjusted HR (ICS [high dose]) 2·30, 95% CI (1·64–3·23)
Adjusted HR ([low or medium dose]) 1·14, 95% CI (0·84–1·54)
Adjusted HR (ICS [high dose]) 1·55, 95% CI (1·10–2·18)
LABA–LAMA combination
SABA only ICS (low or medium dose) ICS (high dose)



























0 20 40 60 80



























LABA–LAMA combination ICS combination
SABA only ICS (low or medium dose) ICS (high dose)
Figure 1: Time to COVID-19-related death for the COPD population (A) and 
asthma population (B), and standardised survival curves for the COPD (C) 
and asthma (D) populations
In panels C and D, the solid line shows the standardised cumulative mortality, 
and the shaded area the 95% CI. COPD=chronic obstructive pulmonary disease. 
HR=hazard ratio. ICS=inhaled corticosteroid. LABA=long-acting β agonist. 
LAMA=long-acting muscarinic antagonist. SABA=short-acting β agonist.  
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variables. Decisions regarding treatment choices involve 
factors that might not be well recorded in EHRs, including 
measures such as spirometry and probable steroid 
responsiveness. Other important unmeasured markers of 
severity include the use of home oxygen therapy, 
which is typically not issued as a prescription by English 
primary care physicians. Because we did not have 
secondary care data, our assessment of exacerbation 
history was incom plete, restricting our ability to adjust for 
this variable. Our sensitivity analyses suggest that 
moderate unmeasured confounding is a plausible 
reason for the harmful associations we observed. Another 
important consideration is the risk of exposure mis-
classification. Some patients might have been incorrectly 
classified as being exposed to ICS, when in reality they 
were not using these medications. Using prescription 
frequency before the English lockdown (which started on 
March 23, 2020) as a proxy for adherence to identify 
patients who are more likely to be regular users would 
probably be relatively inaccurate, both due to the risk of 
as-needed use of some inhalers and the stockpiling of 
inhalers before the start of the UK lockdown.40 We found 
some evidence that the proportional hazards assumption 
was not met for the COPD models, with Kaplan-Meier 
plots indicating that the HR for exposure to ICS versus 
LABA–LAMA increased over time. This observation is 
perhaps not surprising, because the risk of acquiring 
COVID-19 was lower in early March, 2020, before 
lockdown, when SARS-CoV-2 was more widespread. The 
HR for risk of COVID-19-related death in the COPD 
population should be interpreted as an average over the 
entire follow-up period. Finally, the outcome of 
COVID-19-related death will reflect the risk both 
of becoming infected with SARS-CoV-2 and the risk of 
devel oping severe disease and dying. ICS use might have 
a different effect on the risk of infection and on disease 
severity. We were not able to explore the relative 
contribution of ICS use on each of these endpoints in our 
study because of the absence of complete or representative 
data on rates of infection with SARS-CoV-2 in the UK. Test 
result datasets are not an adequate proxy for these data 
because tests have largely been restricted to patients who 
already have relatively severe disease and so are not 
representative of rates of infection in the general 
population. This situation might change as testing 
capacity expands and other studies might be able to test 
these hypotheses in the future. However, if ICS use had a 
strong protective effect on the risk of SARS-CoV-2 
infection, we would expect to see this association via a 
reduced rate of COVID-19-related mortality compared 
with people given alternative treatments because infection 
is considerably more common than death. In terms of 
generalisability, we did not expect the pharmacological 
effect of ICS use on COVID-19-related outcomes to vary 
substantially according to the distribution of population 
characteristics; however, because this effect has not been 
widely studied to date, our findings might not be 
generalisable to other settings or populations. Finally, this 
study has addressed whether people prescribed ICS for 
use in asthma or COPD had reduced COVID-19-related 
mortality compared with those prescribed other 
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Figure 2: Forest plot of COVID-19-related deaths in the COPD population, overall and sensitivity analyses
COPD=chronic obstructive pulmonary disease. HR=hazard ratio. ICS=inhaled cortecosteroid. LABA=long-acting β agonist. LAMA=long-acting muscarinic antagonist.
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have not assessed the role of ICS use in treating COVID-19 
among patients without asthma or COPD; ongoing trials 
will provide evidence on this matter (NCT04331054, 
NCT04330586).
The totality of the data presented here, including our 
sensitivity analyses, do not indicate that regular ICS 
therapy for asthma or COPD either decreases or increases 
risk of death from COVID-19, and do not provide 
evidence to support adjustments in ICS therapy among 
patients with asthma or COPD during outbreaks of 
SARS-CoV-2. The absence of evidence for a protective 
effect implies that alternative explanations for the 
observed under-representation of chronic respiratory 
disease in early epidemiological studies of patients with 
COVID-19 should be explored in future studies. Because 
the small observed increased risk of death is unlikely to 
be causal, our results should also provide reassurance to 
patients relying on ICSs that the use of these medications 
have not put them at undue risk of negative outcomes 
during the ongoing pandemic. Finally, we note that 
future observational studies of this clinical question are 
likely to face similar challenges around unmeasured 
confounding as those described here and we encourage 
researchers to undertake appropriate sensitivity analyses 
where possible.
The UK has an unusually large volume of detailed 
longitudinal patient data. We have shown that it is 
feasible to rapidly address specific hypotheses about 
medicines in a transparent manner inside the secure 
environment of an EHR vendor to minimise the large 
volumes of potentially disclosive data that would 
otherwise have to move into separate systems. We will 
use the OpenSAFELY platform to further inform the 
global response about drug treatments during the 
COVID-19 emergency.
In summary, we found no evidence of a beneficial 
effect of regular ICS use among people with COPD and 
asthma on COVID-19-related mortality. Although we 
report a small harmful association, the pattern of results 
we observed suggests this association could readily be 
explained by differences in underlying health between 
people prescribed ICSs and those prescribed other 
respiratory medications. These results do not support 
any change to the current clinical guidelines for the 
routine treatment of people with COPD or asthma with 
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Figure 3: Forest pot of COVID-19-related deaths in the asthma population, overall and sensitivity analyses 
HR=hazard ratio. ICS=inhaled cortecosteroid. SABA=short-acting β agonist.
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